Newly published data indicate that patients with blinatumomab-sensitive B-precursor acute lymphoblastic leukaemia (B-ALL) have significantly fewer regulatory T cells (Treg) than those with blinatumomab-refractory B-ALL. This observation is attributed to IL-10 production by blinatumomab-activated Treg cells, resulting in suppression of T-cell proliferation, and highlights that Treg enumeration prior to treatment has the potential to identify 70% of nonresponders and thus might spare these patients from receiving an ineffective treatment.
References
Duell, J. et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia http://dx.doi.org/10.1038/leu.2017.41 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Treg predict responsiveness to blinatumomab. Nat Rev Clin Oncol 14, 262 (2017). https://doi.org/10.1038/nrclinonc.2017.36
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.36